Rising Pharmaceuticals launches generic Sustiva
Aceto’s generics subsidiary Rising Pharmaceuticals has introduced a generic of Bristol Myers Squibb’s Sustiva (efavirenz) capsules. The drug is indicated to treat HIV-1 infections in adults and pediatric patients.
The Port Washington, N.Y.-based company’s generic will be available in 50- and 200-mg dosage strengths. The product had U.S. sales of roughly $4.21 million for the 12 months ended October 2017, according to IQVIA data.
Rising currently has more than 120 products on the U.S. market, with a portfolio that includes 50 drugs with pending abbreviated new drug applications or launches, the company said.